Metformin for Prediabetes
What current evidence and guidelines say about using metformin to delay progression to type 2 diabetes in adults at increased risk.
Evidence summary
Evidence supports benefit in selected high-risk adults
The Diabetes Prevention Program showed that metformin reduced progression to type 2 diabetes compared with placebo, although intensive lifestyle intervention produced a larger reduction during the original trial. ADA 2026 recommends considering metformin particularly for adults at high risk, rather than treating every person with prediabetes the same way.
- Population
- Adults at increased risk of type 2 diabetes
- Main outcome
- Progression to type 2 diabetes
- Key comparison
- Placebo / intensive lifestyle intervention
Evidence question
What question does this profile answer?
In adults with prediabetes or otherwise high risk of type 2 diabetes, does metformin delay or reduce progression to type 2 diabetes?
- Medicine
- Metformin →
- Use / condition
- Prediabetes / prevention or delay of type 2 diabetes
- Comparator
- Placebo, standard care, lifestyle intervention
- Main outcomes
- Diabetes incidence, diabetes-free survival, glycaemic outcomes
Synthesis
What the evidence shows
In the original Diabetes Prevention Program, metformin reduced the chance of developing type 2 diabetes by 31% versus placebo over about three years. Intensive lifestyle intervention reduced the chance by 58% versus placebo in the same trial. The 2026 ADA Standards describe metformin as the pharmacologic option with the most robust efficacy and safety data for diabetes prevention among people with prediabetes.
Long-term follow-up continues to show lower diabetes incidence in the metformin and lifestyle groups compared with placebo, but ADA notes that much of the overall treatment effect was established during the original DPP phase. Evidence is therefore best interpreted as risk reduction or delay in defined high-risk populations—not as a universal indication for everyone with a prediabetes label.
Major evidence
Guidelines and landmark trial evidence
American Diabetes Association Standards of Care
Recommends considering metformin for prevention of type 2 diabetes in adults at high risk, especially ages 25–59 with BMI ≥35 kg/m², higher fasting glucose, higher A1C, or prior gestational diabetes.
Open guideline →Diabetes Prevention Program (DPP)
NIDDK summarizes the original result as a 31% reduction in progression to type 2 diabetes with metformin versus placebo, compared with 58% for the intensive lifestyle intervention.
Open NIDDK DPP summary →Population context
Who may benefit according to current guidance?
These are characteristics of populations in which ADA 2026 particularly highlights metformin consideration; they are not a self-treatment checklist.
One group emphasized in the ADA recommendation.
DPP subgroup evidence suggests greater relative benefit in people with higher BMI.
ADA specifically highlights higher-risk glycaemic ranges within prediabetes.
Another population explicitly highlighted by ADA.
Limits of inference
What this evidence does not show
- It does not mean metformin is appropriate for every person with prediabetes.
- It does not make metformin a substitute for evidence-based lifestyle intervention; in the original DPP, lifestyle intervention produced a larger reduction in diabetes incidence.
- It does not establish that starting glucose-lowering medication before diabetes universally improves every long-term health outcome. ADA 2026 explicitly notes uncertainty about long-term health outcomes from early pharmacologic glucose lowering.
- It does not remove the need to consider kidney function, vitamin B12 risk, tolerability and the person’s wider clinical context.
Comparison context
Metformin and intensive lifestyle intervention in the DPP
| DPP arm | Reduction vs placebo | How to interpret it |
|---|---|---|
| Metformin | 31% | Meaningful pharmacologic risk reduction in the trial population. |
| Intensive lifestyle intervention | 58% | Larger reduction during the original DPP phase; effects and feasibility differ by individual and setting. |
These percentages describe relative reductions versus placebo in the original DPP and should not be treated as an individual prediction.
Safety context
Evidence of benefit is separate from suitability
Metformin’s established safety profile still requires product-specific assessment. Long-term use can be associated with reduced vitamin B12 levels, and renal function is central to safe use. The evidence profile therefore links back to the full medicine reference rather than repeating all prescribing information here.
View full Metformin reference →Sources & methodology
Evidence sources
- American Diabetes Association — Standards of Care in Diabetes 2026, Section 3Current guideline recommendations and interpretation of DPP/DPPOS evidence.
- NIDDK — Diabetes Prevention Program (DPP)Landmark trial summary, including 31% metformin and 58% lifestyle reductions versus placebo.
- DailyMed — Metformin hydrochloride prescribing informationProduct-level safety and indication context for metformin.
This evidence summary is based on trusted medical sources and is awaiting clinician review. It is not a substitute for personalized medical advice.